Atrogi

Atrogi is a privately held, clinical-stage biotech company developing next-generation oral therapies targeting major metabolic disorders. Its lead candidate, ATR-258, has completed Phase I and is poised for Phase II trials, backed by a strong IP portfolio and over EUR 20 million in funding. The company's unique approach centers on novel β2-adrenergic receptor agonists that aim to avoid receptor desensitization, potentially enabling effective long-term treatment for conditions like type 2 diabetes and muscle wasting. With a seasoned leadership team and recognition in top-tier journals, Atrogi is positioned to address a massive and growing global market.

Proprietary platform for developing novel, desensitization-resistant β2-adrenergic receptor (β2-AR) agonists for chronic oral use in metabolic diseases.

Atrogi competes in the crowded metabolic disease therapeutic area against large pharma (e.g., Novo Nordisk, Eli Lilly with GLP-1s) and other biotechs. Its differentiation hinges on its novel β2-AR agonist platform aiming to avoid desensitization and potentially offer benefits on both metabolism and muscle, a combination not common in current therapies.